3% and 5% Sodium Chloride Injection, USP in VIAFLEX Plastic Container | Sodium Chloride
3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents. Composition, ionic concentration, osmolarity, and pH are shown in Table 1.
The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
|Size (mL)||Composition (g/L)||Ionic Concentration (mEq/L)||
|Sodium Chloride, USP (NaCl)||Sodium||Chloride|
|3% Sodium Chloride Injection, USP||500||30||513||513||1027||5.0 (4.5 to 7.0)|
|5% Sodium Chloride Injection, USP||500||50||856||856||1711||5.0 (4.5 to 7.0)|
3% and 5% Sodium Chloride Injection, USP has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient.
3% and 5% Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.
3% and 5% Sodium Chloride Injection, USP is strongly hypertonic and may cause vein damage.
3% and 5% Sodium Chloride Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention.
In patients with diminished renal function, administration of 3% and 5% Sodium Chloride Injection, USP may result in sodium retention.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Caution must be exercised in the administration of 3% and 5% Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin.
Animal reproduction studies have not been conducted with 3% and 5% Sodium Chloride Injection, USP. It is also not known whether 3% and 5% Sodium Chloride Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 3% and 5% Sodium Chloride Injection, USP should be given to a pregnant woman only if clearly needed.
Safety and effectiveness of 3% and 5% Sodium Chloride Injection, USP in pediatric patients have not been established by adequate and well controlled trials, however, the use of sodium chloride solutions in the pediatric population is referenced in the medical literature. The warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population.
Clinical studies of 3% and 5% Sodium Chloride Injection, USP, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Do not administer unless solution is clear and seal is intact.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
As directed by a physician. Dosage is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.
All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment.
Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.
3% and 5% Sodium Chloride Injection, USP in VIAFLEX plastic container is available as follows:
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.
|Code||Size (mL)||NDC||Product Name|
|2B1353||500||0338-0054-03||3% Sodium Chloride Injection, USP|
|2B1373||500||0338-0056-03||5% Sodium Chloride Injection, USP|
Warning: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.
Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below.
Warning: Additives may be incompatible.
Baxter Healthcare Corporation
Deerfield, IL 60015 USA
Printed in USA
*BAR CODE POSITION ONLY
Rev. March 2005
Baxter, VIAFLEX, and PL 146 are trademarks ofBaxter International Inc.
3% Sodium Chloride Injection USP
EACH 100 mL CONTAINS 3 g SODIUM CHLORIDE USPpH MAY HAVE BEEN ADJUSTED WITH HYDROCHLORIC ACIDpH 5.0 (4.5 TO 7.0) mEq/L SODIUM 513 CHLORIDE 513OSMOLARITY 1027 mOsmol/L (CALC) HYPERTONIC MAY CAUSEVEIN DAMAGE STERILE NONPYROGENIC SINGLE DOSE CONTAINERADDITIVES MAY BE INCOMPATIBLE CONSULT WITH PHARMACIST IFAVAILABLE WHEN INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUEMIX THOROUGHLY DO NOT STORE DOSAGE INTRAVENOUSLY ASDIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZEAND INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITYDISCARD IF LEAKS ARE FOUND MUST NOT BE USED IN SERIESCONNECTIONS DO NOT USE UNLESS SOLUTION IS CLEAR RX ONLYSTORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOMTEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOIDEXCESSIVE HEAT SEE INSERT
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OFBAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION 1-800-933-0303
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
3% SODIUM CHLORIDEINJECTION, USP
SECONDARY BAR CODE
(17) YYMM00 (10) XXXXX
PRIMARY BAR CODE
Drugs and Medications
This study involves using both a device that seals the capsular bag (where the lens is located) allowing safer irrigation of the capsular bag and sodium chloride to irrigate the capsular b...
The objective of this study is to assess the efficacy of sodium bicarbonate compared with sodium chloride and oral N-acetylcysteine (NAC ) pretreatment for prevention of contrast nephropat...
Sodium pyruvate in sodium chloride solution will be delivered by nebulization to the lungs. It is believed that this administration will produce bronchodilation in asthmatics as determined...
Patients resuscitated with 4% Albumin will have less incidence and reduced severity of pressure injuries than patients resuscitated with 0.9% Sodium Chloride due to the improved intravascu...
The aim of the study is to test the efficacy of low versus high volume hydration and two different solutions (sodium chloride versus sodium bicarbonate) in preventing contrast induced neph...
Laccases produced by white rot fungi have been extensively evaluated for their potential to decolorize textile wastewaters which contain salts like sodium chloride and sodium sulfate. The effect of so...
BACKGROUND: The ACP 215 was a functional closed system for preparing glycerolized and deglycerolized RBCs, CSBT had approved the technique of long term storage glycerolized rare blood lower than -65 d...
PURPOSE: The stability of polymyxin B sulfate in infusion bags containing 0.9% sodium chloride injection stored at 4 and 25 degrees C was studied. METHODS: Seven manufacturing batches of polymyxin B f...
Neurotransmitter:sodium symporters are crucial for efficient synaptic transmission. The transporter GAT-1 mediates electrogenic cotransport of GABA, sodium, and chloride. The presence of chloride enab...
PURPOSE: The stability of doripenem 500 and 1000 mg in polyvinyl chloride (PVC) bags and elastomeric pumps at various storage temperatures was evaluated. METHODS: Commercially available doripenem vial...